OR WAIT null SECS
August 18, 2021
FDA approves Merck’s Welireg for the treatment of adult patients with von Hippel-Lindau disease who require therapy for tumor growth.
WHO’s solidarity plus trial will enroll hospitalized patients to test artesunate, imatinib, and infliximab in hospitalized COVID-19 patients.
BlackBerry’s QNX real-time operating system may create cybersecurity vulnerabilities, according to FDA.
Lilly’s insulin, lyumjev, receives FDA approval for an expanded label.
Cipla receives final approval from FDA for its abbreviated new drug application for difluprednate ophthalmic emulsion 0.05%.
TriRx hosts various leaders at a ribbon-cutting ceremony for their new facility.
BlueAllele has been granted a US patent for its advanced gene-editing technology, PALIDON, which is compatible with existing gene editing nucleases and delivery systems.
The Cleveland, Ohio facility will produce critical anti-infective drug products for US hospitals.
Artiva Biotherapeutics’s new R&D and GMP manufacturing center in San Diego, Calif., for NK cell therapies is expected to open in 2022.
August 17, 2021
Thermo Fisher’s manufacturing site in Greenville, NC was recognized for manufacturing excellence.